Akebia Therapeutics (AKBA) Reports Q3 Net Loss of $59.5M, Cash and Cash Equivalents of $207.2M

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 net loss of $59.5M. Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.67 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Worthington Industries (WOR) Misses Q4 EPS by 9c